Markets
Financials outperform amid Trump deregulatory push
Party time! (Brett Coomer/Getty Images)

Deregulatory push has made financial stocks like JPMorgan into low-key market winners

Jamie Dimon appreciates this run-up.

Another day, another record high for JPMorgan Chase and Coinbase — two extremely different companies but both beneficiaries of a deregulatory push that has made financial stocks into outperformers among the S&P 500 over the last 12 months.

JPMorgan, the largest US bank by assets, has rallied in part because it’s seen as a prime beneficiary of growing momentum to ease a post-financial-crisis rule that forced banks to operate with less borrowed money — i.e. more of their own capital. (Being able to operate with more leverage opens up the opportunity to juice profits, but it can also add risk. Remember, these guardrails were put in place after largesses that sent the world spiraling into a generational financial disaster.)

Bank stocks aren’t typically all that exciting, unless you’re really into net interest margins. But they’ve been on a tear: the S&P 500 subindex that tracks banks alone was up 32% over the last year, with giants like JPMorgan up 47%, Morgan Stanley up 45%, Goldman Sachs up 51%, and Wells Fargo up 40%

Coinbase, meanwhile, has exploded since the Senate passed the bi-partisan GENIUS Act on June 17, which regulates so-called crypto “stablecoins.” The bill is the first in what the industry hopes will be a parade of new rules establishing the legitimacy of crypto and linking it to the broader financial sector.

Coinbase is the top performer in the S&P 500 financial sector over the 12 months, rising more than 65%. And the financial sector is the top performer of the index as a whole, rising almost 25% for the last year.

But, of course, in terms of driving the market-cap-weighted S&P 500 Index higher, the information technology sector is the big dog. It has a 33% weighting in the index — thanks to the presence of market cap giants like Nvidia and Microsoft — making it the prime mover of the market.

More Markets

See all Markets
markets

Bullish options flows boost Rivian

EV maker Rivian is up nearly 5% on Monday afternoon as bullish options flows lift the stock ahead of its third-quarter earnings, set to drop next week.

According to Bloomberg, Rivian call options traded outnumber put options more than five to one, for a put/call ratio of less than 0.2 as of 2:38 p.m. ET. That’s significantly less than the 20-day put/call average of 0.4. More than 116,000 call options have changed hands, more than 60% above the full-day average over the past 20 days.

Rivian’s upcoming earnings will measure the automaker’s sales ahead of the expiration of the $7,500 EV tax credit. Since September, Rivian has performed two rounds of layoffs as it seeks to cut costs amid the end of regulatory credits and ahead of next year’s lower-cost SUV launch.

markets

Palantir inks defense deal with Poland, touches new intraday high

Palantir Technologies touched a new intraday high of $192.83 early Monday, as the company rode the China trade truce rally in AI tech stocks and retail favorites.

Palantir also signed a new deal to supply the government of Poland with data, AI, and cybersecurity software, according to Bloomberg.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir CEO Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir CEO Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

markets

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia dropped sharply on Monday after it announced that it’s pausing two late-stage CRISPR gene-editing trials because one patient was hospitalized with liver damage.

Intellia had also disclosed in May that a patient had experienced elevated liver enzymes. The news is a major setback for the company, which currently has no products on the market and is working on a one-time treatment for heart and nerve conditions.

The news dragged down other companies working on CRISPR treatments, including Beam Therapeutics Inc, Crispr Therapeutics, Editas Medicine, and Prime Medicine.

markets

Gold craters as retail traders pull money from commodity ETFs

As its fierce rally begins to fade, it looks like retail traders are waving au revoir to gold.

JPMorgan strategist Arun Jain noted that retail traders have pulled about $120 million from commodity ETFs as of 11 a.m. ET on Monday, a level that stands in the 0.4th percentile relative to its one-year average. The SPDR Gold Shares ETF is down 2.8% as of 11:53 a.m. ET after suffering its worst loss since April 2013 last Tuesday. That day, retail had pulled just $50 million from commodity ETFs by 11 a.m.

The five-session average daily flows into the product hit an all-time high of nearly $1.1 billion last Monday as gold and silver had effectively become the new meme stocks, displaying strong momentum and heavy options activity.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.